NeOnc Technologies Holdings Inc

neonc.com

What Do They Do?

Develops intranasal and oral drug candidates for brain cancers, along with drug-delivery methods for central nervous system conditions.

How Do They Make Money?

The company has no approved products for sale; it received point-in-time payments for compassionate-use access to its technology when it had no further work to perform.

FY2025 revenue

Who Are Their Customers?

It has no products approved for sale and no sales or marketing infrastructure; its product candidates are being tested in clinical trials.

Do Revenues Turn Into Profits?

No. It lost $62.1M in FY2025.

Operating income, FY2025

−145638% of revenue

▲ +715% (Loss) vs FY2024 (−$7.1M, −8605%)

Net income, FY2025

−155404% of revenue

▲ +422% (Loss) vs FY2024 (−$11.9M, −14335%)

Free cash flow, FY2025

−52173% of revenue

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue
Net income: ▲ +151% (Loss); vs −$5.7M in Q2 FY2025

Sep 8, 2026 Company announced a registered direct offering The offering is expected to raise approximately $15 million before fees and expenses.
Aug 12, 2026 NEO100 Phase 2a study met its primary endpoint Results reported six-month progression-free survival of 48.9% and median overall survival of 26.09 months; the company plans to seek FDA guidance on a registrational path.